- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Diabetes A Significant Barrier to Breast Cancer Screening
Women with diabetes are 14 percent less likely to be screened for breast cancer compared to women without diabetes, according to a study. "Managing the demands of a chronic condition such as diabetes is challenging for many women, leaving other preventative actions, like screening for cancer, to fall by the wayside," said a physician and author. "Our study found having diabetes posed a significant barrier to breast cancer screening even after considering a woman's socioeconomic status, a known contributor to disparities in care among women."
Women with diabetes are 14 percent less likely to be screened for breast cancer compared to women without diabetes, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital.
The study, published today in the journal Diabetic Medicine, is the first to examine the influence of socioeconomic status on the gap in mammogram screening among women with diabetes.
"Managing the demands of a chronic condition such as diabetes is challenging for many women, leaving other preventative actions, like screening for cancer, to fall by the wayside," said Dr. Lorraine Lipscombe, a staff physician at Women's College Hospital and an adjunct scientist at ICES. "Our study found having diabetes posed a significant barrier to breast cancer screening even after considering a woman's socioeconomic status, a known contributor to disparities in care among women."
Read the entire report here:
Source: ScienceDaily
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
